02285nas a2200265 4500008004100000245012600041210006900167260001900236300001000255490000600265520142700271653001601698653002001714653002601734653001901760100002501779700002601804700002501830700002001855700002501875700001701900700003101917700002101948856005001969 2017 eng d00aPre-Clinical Toxicological Evaluation of Rostellularia diffusa: Hematological, Biochemical, and Histopathological Studies0 aPreClinical Toxicological Evaluation of Rostellularia diffusa He cSeptember 2017 a66-690 v33 a
Background: Rostellularia diffusa (Willd.) is a traditional herb belongs to acanthaceae family. The whole plants are used as brain tonic in traditional practice. There were no earlier reports on the safety assessment of Rostellularia diffusa. Objective: the present study was undertaken to assess the safe use of this plant in traditional practice. Method: The acute oral toxicity study of hydro alcoholic extract of Rostellularia diffusa (AERD) was carried out as per the OECD guidelines 423 and the sub-acute toxicity was carried out at a dose of 150 mg/kg and 300 mg/kg as per OECD 407 guidelines in male and female rats. Results: Rats were administered up to 2000 mg/kg as a single dose orally not caused any signs of toxicity or mortality in rats. In sub-acute toxicity study in rats, AERD at two different daily doses of 150 and 300 mg/kg for 14 days did not cause any significant change including the hematological and biochemical parameters. Histopathological examinations showed normal architecture suggesting no morphological disturbances. Conclusion: No deaths or any signs of toxicity was observed after oral administration in acute toxicity study up to a dose of 2000 mg/kg of AERD in rats and up to a dose of 300 mg/kg of AERD in sub-acute toxicity study in rats.
10aBrain tonic10aHerbal medicine10aRostellularia diffusa10aToxicity study1 aSaleem, Mohamed, T S1 aV, Chinni, Krishnaiah1 aSoumya, Gannepureddy1 aBurra, Sowjanya1 aHafeez, Shaik, Abdul1 aBabu, Repana1 aKumar, Peddamoyana, Rajesh1 aChakka, Gopinath uhttps://www.ptbreports.org/article/2017/3/3-3